Takeda Pharmaceutical (TAK) analyst forecast and price target
Analyst forecast
Consensus of 17 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| TD Cowen | Maintained | Outperform | $20.00 from $30.00 | May 16, 2023 |
| TD Cowen | Maintained | Outperform | $30.00 from $24.00 | Apr 4, 2023 |
| B of A Securities | Upgraded | Neutral → Buy | $20.00 | Mar 16, 2023 |
Frequently asked questions
Is TAK a buy, sell, or hold?
Analysts covering Takeda Pharmaceutical currently average a Buy rating: 10 buy, 7 hold and 0 sell, from 17 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on TAK?
On May 16, 2023, TD Cowen maintained Takeda Pharmaceutical at Outperform with a price target of $20.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.